- Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition2021 | Second Faculty of Medicine
- Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial2023 | First Faculty of Medicine
- The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study2016 | Faculty of Medicine in Hradec Králové
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial2018 | First Faculty of Medicine
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial2018 | First Faculty of Medicine
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib2015 | Publication without faculty affiliation